NDA 205598 · Aeterna Zentaris
Macrilen
Macimorelin Acetate · Oral · Growth Hormone Secretagogue Receptor Agonist
NovelOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 20, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 0 recruiting
FAERS reports
5
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2026.
MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD). MACRILEN is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency ( 1 ). Limitations of Use : The safety and diagnostic performance has not been established for subjects with BMI > 40kg/m 2 ( 1 ). Limitations of Use The safety and diagnostic performance of MACRILEN have not been established for subjects with a body mass index (BMI) > 40 kg/m 2 .
Mechanism: Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2026 Supplement 5 · Efficacy · priority review OrphanLetterLabel
- Dec 20, 2017 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- MACRILEN · MACIMORELIN ACETATE EQ 60MG BASE/POUCH · FOR SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Macimorelin" as an intervention, any sponsor and status, largest first.
- Validation of Macimorelin as a Test for Adult Growth Hormone DeficiencyPivotal-lookingCompleted
AEterna ZentarisIndustry
NCT02558829 · 157 participants · Start Dec 3, 2015 · Primary completion Nov 29, 2016
Drug: Macimorelin; Insulin · For: Growth Hormone Deficiency With Pituitary Anomalies
Sites: Torrance, California; Austin, Texas; Houston, Texas · 27 sites in all
- A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it isPivotal-lookingCompleted
AEterna ZentarisIndustry
NCT04786873 · 101 participants · Start Nov 16, 2021 · Primary completion Jun 13, 2024
Drug: Macimorelin · For: Growth Hormone Deficiency
Sites: Tucson, Arizona; Greenwood Village, Colorado; St. Petersburg, Florida · 45 sites in all
- Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.Pivotal-lookingCompleted
AEterna ZentarisIndustry
NCT00448747 · 101 participants · Start Jun 2007 · Primary completion Jul 2011
Drug: AEZS-130 (formerly ARD-07); L-ARG+GHRH · For: Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Sites: Tempe, Arizona; Los Angeles, California; Torrance, California · 13 sites in all
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT00377377 · 42 participants · Start Nov 2005
Drug: EP1572 (ghrelin agonist) oral and duodenal application · For: Healthy Subjects
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT03844217 · 28 participants · Start Mar 7, 2019 · Primary completion Jul 16, 2019
Drug: Macimorelin 0.5mg/kg body weight; Macimorelin 0.75mg/kg body weight · For: Polyuria-polydipsia Syndrome
Sites: Basel, Switzerland
Garcia, Jose M., MD, PhDIndividual
NCT01614990 · 15 participants · Start May 2012 · Primary completion Jul 2020
Drug: Macimorelin; Placebo · For: Cancer Cachexia
Sites: Seattle, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bradycardia1
- dizziness1
- dysgeusia1
- fatigue1
- feeling hot1
- fluid retention1
- flushing1
- nausea1
- off label use1
- product communication issue1
- therapeutic product effect variable1
- wrong technique in product usage process1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia.
Herodes M, Anderson LJ, Shober S, et al. · J Cachexia Sarcopenia Muscle 2023 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Macimorelin as a Diagnostic Test for Adult GH Deficiency.
Garcia JM, Biller BMK, Korbonits M, et al. · J Clin Endocrinol Metab 2018 · Clinical Trial, Phase III, Multicenter Study
- Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants.
Lissy M, Demmel V, Sachse R, et al. · Clin Pharmacol Drug Dev 2021 · Clinical Trial, Phase I, Comparative Study
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.
Klaus B, Sachse R, Ammer N, et al. · Growth Horm IGF Res 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Aeterna Zentaris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.